Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

Eleanor Clancy-Thompson, Lestat Ali, Patrick T. Bruck, Mark A. Exley, Richard S. Blumberg, Glenn Dranoff, Michael Dougan and Stephanie K. Dougan
Eleanor Clancy-Thompson
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lestat Ali
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick T. Bruck
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Exley
2Beth Israel Deaconess Medical Center, Boston, Massachusetts.
3Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.
4Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard S. Blumberg
3Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.
4Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn Dranoff
4Harvard Medical School, Boston, Massachusetts.
5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Dougan
4Harvard Medical School, Boston, Massachusetts.
5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
6Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Stephanie_Dougan@dfci.harvard.edu mldougan@partners.org
Stephanie K. Dougan
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
4Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Stephanie_Dougan@dfci.harvard.edu mldougan@partners.org
DOI: 10.1158/2326-6066.CIR-17-0490 Published January 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    iNKT-cell development in FTOC is blocked by IAP antagonists. A–D, Thymii from E16.5 embryos were cultured in the presence of IAP antagonists (LBW-242, LCL-161, LCJ-917), vehicle (−), or control compound (LCV-843) for 14 days. Control and LBW-242 were used at 500 nmol/L or as indicated; LCL-161 and LCJ-617 were used at 200 nmol/L. A, α-GalCer-loaded CD1d tetramer+ iNKT cells were identified in FTOC using flow cytometry. B, Quantification of results from three independent experiments performed and analyzed as in A. C, Dose–response curve for LBW-242 in FTOC. D, Cells recovered from FTOC were stimulated with anti-CD3 without further exposure to IAP antagonists; labels indicate the compounds added during thymic culture. IL2 was measured in the culture supernatant by ELISA. E, Foxp3-positive thymocytes were identified in LBW-242–treated cultures using thymi harvested from Foxp3-GFP knock-in embryos. F, γδ T cells were identified in LCL-161– and LCJ-917–treated cultures by δ chain expression. D–F, Error bars represent SEM. Results are representative of at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant versus control.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Mature iNKT cells persist in IAP antagonist–treated cultures. A, FTOC were performed as in Fig. 1 in the presence of LBW-242 or control compound (continuous treatment) or were cultured in the absence of compound until day 14 when LBW-242 or control compound were added (late addition). All cultures were harvested at day 16 and analyzed by flow cytometry. B, Spleen cells (5 × 105) were cultured in the presence of LBW-242 or control compound; after 24 hours, total viable cells were quantified by Trypan blue exclusion, and T cells and iNKT cells were identified by flow cytometry. Error bars present SEM. A and B, Results are representative of two independent experiments.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    IAP antagonists enhance cytokine production from mature iNKT cells. A, Spleen cells (5 × 105) were treated with (α-GalCer) or vehicle in the presence of LBW-242 or control compound (LCV-843) for 24 hours. B, The iNKT-cell hybridomas 24.7, 24.8, and 24.9 were stimulated with anti-CD3 (10 μg/mL) for 24 hours in the presence of LBW-242 or control compound. C, Whole spleens from transnuclear mice (Vβ7A, Vβ7C, and Vβ8.2 on a RAG2−/− background) were inflated with PBS before homogenization and plating at 2 × 105 cells per well in a 96-well plate, with 1 μg/mL, 500 ng/mL, 100 ng/mL, 50 ng/mL, 10 ng/mL, 5 ng/mL, or 0 ng/mL α-GalCer with or without 500 nmol/L LCL-161, as indicated. Supernatants were collected after 24 hours. A–C, Cytokines were measured by ELISA. Error bars represent SEM. Results represent two independent experiments with six replicas per experiment. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 versus control.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    IAP antagonism costimulates cytokine production from conventional CD8+ and CD4+ T cells, as well as invariant NKT cells. CD8+ and CD4+ T cells were isolated from C57BL/6 mice by magnetic bead separation and plated at 1.5 × 105 cells per well in a 96-well plate. Whole spleens from Vα14 transnuclear mice were inflated with PBS, homogenized, and plated at 1.5 × 105 cells per well. LCL-161 depicts cells treated with 500 nmol/L LCL-161 without stimulation. C57BL6 CD4 and CD8 T cells were stimulated with anti-CD3/anti-CD28 beads, whereas Vα14 spleen cells were stimulated with 100 ng/mL α-GalCer. Supernatants were collected after 48 hours of culture and analyzed by cytokine bead array. Results are representative of two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    In vivo effects of IAP antagonist plus α-GalCer on cytokine production and on B16F10 lung metastases. A–C, All C57BL/6 mice were treated with vehicle or LCL-161 (75 mg/kg) by oral gavage at days −2 and day 0 of analysis. A, On day 0, LCL-161 or vehicle-treated mice were injected intraperitoneally with 1 μg α-GalCer and bled 2 hours after injection. Serum was collected and analyzed by ELISA. B, On day 0, LCL-161 or vehicle-treated mice were treated with 1 μg α-GalCer intraperitoneally; 4 hours after stimulation, mice were sacrificed and their spleens were homogenized and stained with anti-CD3 and PBS57-CD1d tetramer before being fixed, permeabilized, and stained intracellularly with anti-IL2 and anti-IFNγ. Representative flow plots are gated on CD3+Tetramer+ iNKT cells. C, Mice were treated with vehicle or LCL-161 (75 mg/kg) by oral gavage 2 days prior to, and on the day of tumor inoculation. Mice were injected with B16F10 cells (3 × 105) intravenously. Four hours after inoculation, and again on days 4 and 8, mice were treated with vehicle or 1 μg α-GalCer intraperitoneally. On day 14, mice were sacrificed, and lung nodules in the right lobe were enumerated and quantified. A–C, Results are representative of three independent experiments. *, P < 0.05; ***, P < 0.001.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Effect of IAP antagonist treatment on cultured human invariant NKT-cell IFNγ production and overall yield. A, B, Human peripheral blood mononuclear cells were depleted of CD14+ cells and cultured with α-GalCer (1 μg/mL) and LBW-242 (500 nmol/L) as indicated. IFNγ (A) and IL-4 (B) production were determined by ELISA of 48-hour culture supernatants. C, Human peripheral blood mononuclear cells were cultured with α-GalCer with or without LBW-242 or were left untreated. After 2 weeks, invariant NKT cells were identified by flow cytometry using coexpression of Vα24 and Vβ11, and total cultured cells were quantified by Trypan blue exclusion. Results are representative of three independent experiments. **, P < 0.01; ****, P < 0.0001.

Additional Files

  • Figures
  • Supplementary Data

    • Supplemental Figure Legends - Figure legends
    • Figure S1 - S1: Structure of IAP antagonists
    • Figure S2 - S2: IAP antagonist treatment skewsT-cell development toward the CD8 lineage in fetal thymic organ culture (FTOC).
    • Figure S3 - S3: IAP antagonism alone does not induce apoptosis of iNKT cells or conventional T cells.
    • Figure S4 - S4: CD1d knockout mice show a significant contribution of the costimulatory effects of LBW-242 on cytokine production by CD4+ T cells.
PreviousNext
Back to top
Cancer Immunology Research: 6 (1)
January 2018
Volume 6, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
Eleanor Clancy-Thompson, Lestat Ali, Patrick T. Bruck, Mark A. Exley, Richard S. Blumberg, Glenn Dranoff, Michael Dougan and Stephanie K. Dougan
Cancer Immunol Res January 1 2018 (6) (1) 25-35; DOI: 10.1158/2326-6066.CIR-17-0490

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
Eleanor Clancy-Thompson, Lestat Ali, Patrick T. Bruck, Mark A. Exley, Richard S. Blumberg, Glenn Dranoff, Michael Dougan and Stephanie K. Dougan
Cancer Immunol Res January 1 2018 (6) (1) 25-35; DOI: 10.1158/2326-6066.CIR-17-0490
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • TGF Influences Alternative Splicing of Irf1 in Th1 Cells
  • Machine Learning–Based Prognostic Marker of HCC
  • Lenalidomide Turns Myeloma-Associated Macrophage Tumoricidal
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement